The short version
Only one company currently supplies this market — there is no backup if it stumbles.
Market view
nelarabine · Injection, Solution
2 marketed package NDCs · 1 active manufacturer
Most dispensed: 5 mg/mL · Injection · #1 vial/carton / 50 ml in 1 vial · 5 mg/mL · Injection · #1 vial, single-dose/carton / 50 ml in 1 vial, single-dose · 5 mg/mL · Injection · #6 vial, single-doses/carton / 50 ml in 1 vial, single-dose · 5 mg/mL · Injection · #6 vials/carton / 50 ml in 1 vial
Same drug class
Other molecules FDA puts in Nucleoside Metabolic Inhibitor, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
- pentostatin· in shortage
- azacitidine· in shortage
- (daunorubicin and cytarabine) liposome· 1 maker
- azacitidine for· 1 maker
- fluorouracil cream, 0.5%· 1 maker
- gemcitabine intravesical· 1 maker
- purixan· 1 maker
- trifluridine and tipiracil· 1 maker
- cedazuridine and decitabine· 3 makers
- trifluridine· 6 makers
- mercaptopurine· 7 makers
- cytarabine· 9 makers
Common questions
- Is Nelarabine in shortage right now?
- No. FDA does not currently list Nelarabine in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Nelarabine?
- 19 companies have marketed Nelarabine in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.